Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity

Our results indicate that activation of PAR-1 contributes to Dox-induced cardiotoxicity. Inhibition of PAR-1 may be a new approach to reduce Dox-induced cardiotoxicity in cancer patients.